Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Brief Summary: The primary objective was to demonstrate the effect of teriflunomide (HMR1726) (14 milligram per day \[mg/day\] and 7 mg/day), in comparison to placebo, for reducing conversion of participants presenting with their first clinical episode consistent with multiple sclerosis (MS) to clinically definite multiple sclerosis (CDMS).

The secondary objectives were:

* To demonstrate the effect of teriflunomide, in comparison to placebo, on:

  * Reducing conversion to definite multiple sclerosis (DMS)
  * Reducing annualized relapse rate (ARR)
  * Reducing disease activity/progression as measured by Magnetic Resonance Imaging (MRI)
  * Reducing accumulation of disability for at least 12 weeks as measured by the Expanded Disability Status Scale (EDSS)
  * Proportion of disability-free participants as assessed by the EDSS
  * Reducing participant-reported fatigue
* To evaluate the safety and tolerability of teriflunomide
* To evaluate the pharmacokinetics (PK) of teriflunomide
* Optional pharmacogenomic testing aimed at assessing the association between the main enzyme systems of teriflunomide metabolism and hepatic safety, and other potential associations between gene variations and clinical outcomes


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide (drug) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylprednisolone (drug) | Intervention Type: DRUG; Name: Cyclophosphamide (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methylprednisolone (drug); Assigned to Arm(s): 2
C: Arm Label: Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Teriflunomide, Drug: Placebo | Arm Label: Teriflunomide 7 mg/7 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg/14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg, Teriflunomide 14 mg/14 mg, Teriflunomide 7 mg/7 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg
D: Arm Label: Alemtuzumab; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab | Arm Label: Interferon Beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a | Intervention Type: BIOLOGICAL; Name: Alemtuzumab; Assigned to Arm(s): Alemtuzumab | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): Interferon Beta-1a

Answer: C